LY-3454738
- Generic Name
- LY-3454738
A Relative Bioavailability Study of LY3454738 in Healthy Participants
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT06173895
- Locations
- ๐บ๐ธ
ICON Early Phase Services, San Antonio, Texas, United States
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 236
- Registration Number
- NCT05911841
- Locations
- ๐บ๐ธ
Johnson Dermatology, Fort Smith, Arkansas, United States
๐บ๐ธDermatology Research Associates, Los Angeles, California, United States
๐บ๐ธEncore Medical Research, Hollywood, Florida, United States
A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 52
- Registration Number
- NCT04159701
- Locations
- ๐บ๐ธ
California Allergy and Asthma Medical Group + Research Center, Los Angeles, California, United States
๐บ๐ธMiami Dermatology and Laser Research, Miami, Florida, United States
๐บ๐ธKern Research, Inc, Bakersfield, California, United States
A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 128
- Registration Number
- NCT03750643
- Locations
- ๐บ๐ธ
Global Health Research Center, Miami Lakes, Florida, United States
๐บ๐ธPAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore, Maryland, United States
๐บ๐ธRevival Research Corporation, Doral, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.